Last updated on June 2018

Neonatal Vancomycin Trial

Brief description of study

The study aims to compare the efficacy, safety and pharmacokinetics (PK) of an optimised dosing to a standard dosing regimen of vancomycin in neonates and infants aged 90 days with late onset bacterial sepsis known or suspected to be caused by Gram-positive microorganisms

Detailed Study Description

Detailed objectives of the study are:

  • To compare the efficacy of an optimised vancomycin dosing regimen to a standard vancomycin dosing regimen in patients with late onset, bacterial sepsis, known or suspected to be caused by Gram-positive microorganisms.
  • To compare the safety of vancomycin (including renal and hearing safety) by allocation group in the intention to treat (ITT) population
  • To describe the PK parameters according to vancomycin dosing regimen and outcome using population PK modelling in the ITT population
  • To describe PK/PD in terms of the probability of target attainment (PTA) with different vancomycin dosing regimens in the ITT and per protocol (PP) populations
  • To describe outcomes and duration of therapy at the end of vancomycin treatment and at the short term follow-up visit by allocation group in the ITT and PP populations
  • To compare the clinical outcome to the antibacterial susceptibility of infecting organisms
  • To compare colonisation by resistant microorganisms (e.g. vancomycin-resistant enterococci (VRE)) and Candida spp. by allocation group at baseline, TOC and short-term follow-up
  • To validate across multiple centres a host biomarker panel to allow improved diagnosis of bacterial sepsis and monitor response to antibacterial therapy

Clinical Study Identifier: NCT02790996

Contact Investigators or Research Sites near you

Start Over

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.